Tourmaline Bio Announces Closing of Merger with Talaris

Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular...

Related Keywords

Piper Sandler ,Sandeep Kulkarni ,Exchange Commission ,Nasdaq ,Goodwin Procter ,Great Point Partners ,Talaris Therapeutics Inc ,Tourmaline Bio Inc ,Talaris Therapeutics ,Tourmaline Bio ,Nasdaq Global Market ,Acuta Capital Partners ,Affinity Asset Advisors ,Cowen Healthcare Investments ,Deep Track Capital ,Logos Capital ,Paradigm Biocapital ,Qiming Venture Partners United States ,Stempoint Capital ,Vivo Capital ,Chief Executive Officer ,Guggenheim Securities ,Truist Securities ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Nasdaq Trml ,Nc ,